Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HS-130 |
Synonyms | |
Therapy Description |
HS-130 is a cancer vaccine, expressing a fusion of the OX40 ligand (TNFSF4) to an immunoglobulin, to activate an anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HS-130 | HS130|HS 130 | HS-130 is a cancer vaccine, expressing a fusion of the OX40 ligand (TNFSF4) to an immunoglobulin, to activate an anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|